Equities Analysts Issue Forecasts for Lipocine Q1 Earnings

Lipocine Inc. (NASDAQ:LPCN) – HC Wainwright boosted their Q1 2026 earnings per share estimates for Lipocine in a report issued on Monday, March 30th. HC Wainwright analyst Y. Chen now forecasts that the specialty pharmaceutical company will post earnings of ($0.51) per share for the quarter, up from their prior forecast of ($0.60). HC Wainwright currently has a “Neutral” rating on the stock. HC Wainwright also issued estimates for Lipocine’s Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.47) EPS and FY2026 earnings at ($1.91) EPS.

LPCN has been the subject of several other reports. Wall Street Zen raised Lipocine from a “sell” rating to a “hold” rating in a report on Sunday, March 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lipocine in a report on Friday, March 27th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $15.00.

Lipocine Stock Performance

LPCN stock traded up $0.04 during midday trading on Tuesday, hitting $1.98. 1,341,748 shares of the stock were exchanged, compared to its average volume of 299,658. The stock’s 50-day moving average price is $8.10 and its 200-day moving average price is $5.78. The stock has a market cap of $14.45 million, a price-to-earnings ratio of -1.17 and a beta of 1.09. Lipocine has a fifty-two week low of $1.81 and a fifty-two week high of $12.37.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings data on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.26. The firm had revenue of $1.15 million during the quarter, compared to analysts’ expectations of $0.12 million. Lipocine had a negative return on equity of 59.30% and a negative net margin of 487.00%.

Hedge Funds Weigh In On Lipocine

A number of institutional investors have recently made changes to their positions in LPCN. Squadron Capital Management LLC acquired a new position in shares of Lipocine in the fourth quarter worth $4,256,000. Diadema Partners LP acquired a new position in shares of Lipocine in the fourth quarter worth $2,095,000. Ikarian Capital LLC acquired a new position in shares of Lipocine in the fourth quarter worth $1,602,000. Persistent Asset Partners Ltd acquired a new position in shares of Lipocine in the fourth quarter worth $567,000. Finally, Boothbay Fund Management LLC acquired a new position in shares of Lipocine in the fourth quarter worth $441,000. 9.11% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Lipocine

In related news, CEO Mahesh V. Patel purchased 25,000 shares of the business’s stock in a transaction dated Monday, April 6th. The stock was bought at an average cost of $2.03 per share, with a total value of $50,750.00. Following the completion of the acquisition, the chief executive officer directly owned 160,679 shares in the company, valued at $326,178.37. The trade was a 18.43% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John W. Higuchi purchased 123,000 shares of the business’s stock in a transaction dated Monday, April 6th. The stock was bought at an average cost of $2.05 per share, with a total value of $252,150.00. Following the completion of the acquisition, the director owned 163,797 shares of the company’s stock, valued at approximately $335,783.85. The trade was a 301.49% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have purchased 173,000 shares of company stock valued at $353,400. 6.35% of the stock is currently owned by insiders.

Key Headlines Impacting Lipocine

Here are the key news stories impacting Lipocine this week:

• Positive Sentiment: CEO Mahesh Patel purchased 25,000 shares (~$2.03 avg), increasing his stake ~18%. Insider buying from senior management often signals confidence in the company’s prospects and can support short-term buying interest. Read More.
• Positive Sentiment: Director John W. Higuchi bought 123,000 shares (~$2.05 avg), a large increase in his holding. Substantial director-level purchases can amplify the positive signal from the CEO buy and attract momentum-seeking investors. Read More.
• Neutral Sentiment: HC Wainwright raised its EPS estimates across Q1–Q4 and cut its FY2026 loss forecast to ($1.91) from ($2.27) while maintaining a “Neutral” rating — model improvements but no upgrade. The revisions reduce downside in institutional models but leave the street view unchanged for now.
• Neutral Sentiment: Institutional activity shows modest new/added positions (Citadel, Jane Street, Renaissance, Boothbay, Geode). Total institutional ownership remains low (~9.1%), so inflows are supportive but not yet a major demand driver. Read More.
• Negative Sentiment: Johnson Fistel announced an investigation into potential shareholder claims against Lipocine’s executives. The probe raises litigation risk and could create headline-driven volatility or costs if it advances. Read More.
• Negative Sentiment: Despite a recent quarterly beat (reported March 10), Lipocine remains unprofitable with large negative margins and a history of losses — a structural risk that keeps valuation speculative and makes the stock sensitive to fundraising, clinical progress, or regulatory news. Read More.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.